Viromed Medical AG, a medical technology company specializing in cold plasma technology, has entered into a global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH. The agreement, announced on May 18, 2026, grants NEBU-TEC worldwide exclusive distribution rights for veterinary applications of Viromed's PulmoPlas® platform, combining it with NEBU-TEC's nebulization technology.
The partnership aims to open up new therapeutic applications for respiratory diseases. The initial focus is on veterinary use of PulmoPlas® for pulmonary diseases in horses, addressing a market with significant potential in the European equine industry and equestrian sports, where respiratory conditions are widespread. The market launch of PulmoPlas® vet is scheduled for later in 2026 and does not require approval in this area.
According to the release, NEBU-TEC is an innovative and globally active medical technology company with 30 years of experience in aerosol medicine. It develops, manufactures, and distributes inhalation devices for human and veterinary medicine. The devices used by NEBU-TEC are Class IIa medical devices under the EU Medical Device Regulation (MDR), which paves the way for future use in humans in combination with PulmoPlas® med.
Uwe Perbandt, CEO of Viromed Medical AG, stated: "The partnership with NEBU-TEC represents an important step in the international commercialization of our PulmoPlas® platform. Combining our cold plasma technology with NEBU-TEC's nebulization expertise opens up new fields of application in veterinary medicine and, going forward, also for applications in human medicine. We see attractive market potential here for this innovative approach."
Eike Kern, Managing Director of NEBU-TEC, emphasized: "The combination of inhalative application and cold plasma opens up new therapeutic possibilities. By bringing together complementary technologies, we are creating innovative and safe concepts for the treatment of both animals and humans – effective, safe and forward-looking."
This agreement expands Viromed's strategic partnerships in cold plasma technology and positions PulmoPlas® in additional international markets and fields of application. Viromed Medical AG, listed on the stock exchange since October 2022, focuses on distributing cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. NEBU-TEC, headquartered in Elsenfeld, specializes in state-of-the-art inhalation devices for professional healthcare facilities and home use. More information can be found at www.viromed-medical-ag.de and www.nebu-tec.de.
